Cited 57 times in
High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 심효섭 | - |
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2014-12-19T16:41:35Z | - |
dc.date.available | 2014-12-19T16:41:35Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90011 | - |
dc.description.abstract | PURPOSE: This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma in which EGFR mutations are very rare. EXPERIMENTAL DESIGN: EGFR gene copy numbers were assessed by FISH and evaluated as predictors of EGFR-TKI efficacy in 71 patients with advanced squamous cell lung cancer who received gefitinib or erlotinib as a second-line or higher therapy. The tumors were classified into EGFR/FISH-positive (high polysomy/gene amplification) and EGFR/FISH-negative (other) groups. RESULTS: EGFR/FISH was positive in 19 (26.7%) patients. Only EGFR/FISH positive status was correlated with the EGFR-TKIs response (EGFR/FISH(+) vs. EGFR/FISH(-), 26.3% vs. 2.0%; P = 0.005). In a multivariate analysis, the risk of progression was lower in EGFR/FISH-positive patients (HR of EGFR/FISH(+) vs. EGFR/FISH(-), 0.57; P = 0.057) or patients experiencing grade 2 or more rash (HR for rash grade 2 or more vs. less than 2, 0.54; P = 0.042), compared with EGFR/FISH-negative patients or those experiencing grade of less than 2 rash, respectively. When the combined criteria of EGFR/FISH and skin rash severity were analyzed, EGFR/FISH-negative patients with grade less than 2 rash had poorer clinical outcomes than patients with positive EGFR/FISH or grade 2 or more rash, apparent as a lower response rate (0.0% vs. 21.4%; P = 0.003) and a shorter median progression-free survival (1.13 months vs. 3.90 months; P = 0.0002). CONCLUSIONS: EGFR/FISH and skin rash severity may be used to identify which patients are likely to gain a benefit from EGFR-TKIs in this population. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Carcinoma, Squamous Cell/drug therapy | - |
dc.subject.MESH | Carcinoma, Squamous Cell/genetics* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality | - |
dc.subject.MESH | Exanthema/complications* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Dosage* | - |
dc.subject.MESH | Genes, erbB-1* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy | - |
dc.subject.MESH | Lung Neoplasms/genetics* | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Protein Kinase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/antagonists & inhibitors* | - |
dc.subject.MESH | Retreatment | - |
dc.title | High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Youngjoo Lee | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.contributor.googleauthor | Moo Suk Park | - |
dc.contributor.googleauthor | Joo-Hang Kim | - |
dc.contributor.googleauthor | Sang-Jun Ha | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-11-2582 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A02219 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 22271877 | - |
dc.contributor.alternativeName | Kim, Se Hoon | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Park, Moo Suk | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Kim, Se Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Park, Moo Suk | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.citation.volume | 18 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1760 | - |
dc.citation.endPage | 1768 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.18(6) : 1760-1768, 2012 | - |
dc.identifier.rimsid | 32305 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.